L3VLUP
ProSign in

EXEL · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

EXELGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • EXEL
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterEXELGILD
Q3 202018 holders, $1.8bn25 holders, $14.2bn
Q4 202011 holders, $1.2bn27 holders, $13.4bn
Q1 202113 holders, $1.3bn24 holders, $14.5bn
Q2 202110 holders, $976m18 holders, $14.9bn
Q3 202113 holders, $1.1bn20 holders, $16.4bn
Q4 20219 holders, $922m20 holders, $16.8bn
Q1 202210 holders, $1.2bn28 holders, $13.2bn
Q2 202212 holders, $1.4bn26 holders, $13.6bn
Q3 202211 holders, $630m24 holders, $13.3bn
Q4 202211 holders, $714m32 holders, $21.1bn
Q1 202312 holders, $1.1bn27 holders, $21.8bn
Q2 202310 holders, $976m24 holders, $20.7bn
Q3 202312 holders, $1.1bn24 holders, $20.0bn
Q4 202313 holders, $1.2bn22 holders, $21.5bn
Q1 202411 holders, $1.2bn30 holders, $20.3bn
Q2 202411 holders, $1.1bn28 holders, $18.5bn
Q3 202412 holders, $1.3bn29 holders, $24.2bn
Q4 202413 holders, $1.8bn28 holders, $25.9bn
Q1 202513 holders, $2.0bn33 holders, $32.0bn
Q2 202513 holders, $2.1bn27 holders, $30.9bn
Q3 20259 holders, $2.1bn23 holders, $29.4bn
Q4 202511 holders, $2.3bn25 holders, $34.3bn
Q1 202612 holders, $2.3bn25 holders, $38.5bn
Q2 202615 holders, $3.1bn26 holders, $34.2bn
EXEL

Exelixis Inc

Holders
9
Reported value
$2.1bn
Buyers
5
Sellers
4

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
23
Reported value
$29.4bn
Buyers
9
Sellers
14

Breadth -5 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2025

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only EXEL (4)

Caxton Associates LLP, Farallon Capital Management LLC, First Eagle Investment Management LLC, Voloridge Investment Management LLC

Only GILD (18)

Acadian Asset Management LLC, AllianceBernstein LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →